Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.51 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.48 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TFEB | P19484 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433729 | 1.00 | NFE2L2 (0.54) | NFE2L2KDM4EPTGER4PTGER3PTGER2 | |
| SCHEMBL2424846 | 0.89 | NFE2L2 (0.56) | NFE2L2KDM4ETRPM8CYP1A1CYP1A2 | |
| SCHEMBL3697381 | 0.83 | NFE2L2 (0.61) | NFE2L2KDM4EPTGER4PTGER3PTGER2 | |
| SCHEMBL3697383 | 0.83 | NFE2L2 (0.61) | NFE2L2KDM4EPTGER4PTGER3PTGER2 | |
| SCHEMBL2426624 | 0.82 | MAOB (0.53) | NFE2L2KDM4ETRPM8CYP1A1CYP1A2 | |
| SCHEMBL2426625 | 0.82 | MAOB (0.53) | NFE2L2KDM4ETRPM8CYP1A1CYP1A2 | |
| SCHEMBL2426621 | 0.82 | MAOB (0.53) | NFE2L2KDM4ETRPM8CYP1A1CYP1A2 | |
| SCHEMBL636252 | 0.81 | SRC (0.51) | NFE2L2CYP1A2NPC1RAB9A | |
| SCHEMBL2424687 | 0.81 | NFE2L2 (0.46) | NFE2L2KDM4ETRPM8CYP1A1CYP1A2 | |
| SCHEMBL1056670 | 0.81 | NFE2L2 (0.79) | NFE2L2KDM4ETRPM8CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237659-A1 | CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-09-29 | — | — | US | disclosed |
| EP-2367810-A1 | CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS | Glenmark Pharmaceuticals S.A. (CH) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010055384-A1 | CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237659-A1 | CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS | TRPV3, TRPV2, TRPV1 | NFE2L2 1041/4885KDM4E 3824/4885PTGER4 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.